Topic
Tabernanthine
About: Tabernanthine is a research topic. Over the lifetime, 23 publications have been published within this topic receiving 656 citations.
Papers
TL;DR: In some rats, there were persistent decreases in morphine or cocaine intake for several days after a single injection or after two or three weekly injections of one or another of these alkaloids; R-ibogamine produced such effects more consistently than any of the other alkaloid effects.
199 citations
TL;DR: In this paper, the following new alkaloids were isolated: (+)-quebrachamine (IV), an optical isomer of the known (−)-QBamine; iso voacangine (IIIa); and tabernanthine and ibogamine.
70 citations
TL;DR: In morphine-dependent mice, ibogaine, but not O-desmethylibogaine or O-t-butyl-O-des methylibogane, attenuated naloxone precipitated withdrawal jumping, consistent with the hypothesis that inhibition of the expression of morphine dependence by ibogane is related to its NMDA receptor antagonist properties.
54 citations
TL;DR: The naturally occurring alkaloid ibogaine has been reported to interrupt the cravings for alcohol, cocaine and opiates, and alkaloids from Tabernanthe iboga provide insight into the structure activity relationship at the different receptors believed to be involved in addiction, providing a start for the medicinal chemist to design anti-addictive agents.
Abstract: Chemical substance abuse has tormented mankind throughout history. A number of chemical approaches have been employed in an attempt to treat chemical addiction. Unfortunately, most of these have proven unsuccessful though several chemical entities have been shown to be moderately effective. The naturally occurring alkaloid ibogaine has been reported to interrupt the cravings for alcohol, cocaine and opiates. Other alkaloids from Tabernanthe iboga, such as ibogamine and tabernanthine, provide insight into the structure activity relationship at the different receptors believed to be involved in addiction. The synthetic iboga alkaloid congener, 18-MC, also shows potential as an anti-addictive agent without the hallucinogenic effects of ibogaine. Additionally, acamprosate, BP 897, GBR12909, lofexidine and memantine have shown promising results in the treatment of addiction. All of these leads provide a start for the medicinal chemist to design anti-addictive agents, since currently no drugs are approved in the U.S. for the treatment of addictions to cocaine, methamphetamine, other stimulants or PCP.
47 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2002 | 1 |
| 1999 | 1 |
| 1996 | 1 |
| 1994 | 1 |
| 1991 | 1 |
| 1990 | 1 |